Article Details
Retrieved on: 2021-10-06 14:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca will advance and accelerate ongoing Phase III development of CAEL-101, a potential first-in-class medicine for AL amyloidosis. 10.06.21.
Article found on: www.contractpharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here